Please login to the form below

Not currently logged in
Email:
Password:

Lenvima

This page shows the latest Lenvima news and features for those working in and with pharma, biotech and healthcare.

Merck says it has plenty in the pipe beyond Keytruda

Merck says it has plenty in the pipe beyond Keytruda

AstraZeneca-partnered Lynparza (olaparib) and Eisai-partnered Lenvima (lenvatinib) that the company is also expecting to show significant growth in the coming years.

Latest news

  • Analysts look beyond Keytruda in Merck’s future Analysts look beyond Keytruda in Merck’s future

    Human papillomavirus (HPV) vaccine Gardasil was up a third to $835m, and there were good performances for cancer drugs Lynparza (olaparib) and Lenvima (lenvatinib), partnered with AstraZeneca and Eisai, respectively. ... Responding, the CEO said: “We

  • Eisai’s Lenvima wins European liver cancer indication Eisai’s Lenvima wins European liver cancer indication

    Lenvima however, is already on the European market to treat thyroid cancer, but thanks to positive data from the phase III REFLECT study, Eisai can now add another string to the ... Additionally, Lenvima also demonstrated statistically significant

  • Pfizer’s plans for Inlyta go awry with failed adjuvant trial Pfizer’s plans for Inlyta go awry with failed adjuvant trial

    nivolumab) and Exelixis’ multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).

  • $5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima $5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

    rights for Lenvima (lenvatinib) and start a series of clinical trials in combination with Keytruda (pembrolizumab). ... Eisai reported Lenvima sales of 9.6bn yen (around $90m) in the first six months of its current fiscal year, which ends on 31 March.

  • NICE reverses its rejection of Eisai’s Lenvima NICE reverses its rejection of Eisai’s Lenvima

    However, NICE - the body that weighs up medication costs versus disease effectiveness for NHS England - originally rejected Lenvima last year, claiming in draft guidance the drug was not cost-effective. ... Lenvima, a once-daily oral, works by inhibiting

More from news
Approximately 9 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics